A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been shown to improve progression-free survival when added to standard chemotherapy regimens for lymphoma.

KI fragen

Bookmark

KI fragen

Bookmark

Cite This Study

David G. Maloney (Thu,) studied this question.

synapsesocial.com/papers/69d9af2b387cf7069868519b https://doi.org/https://doi.org/10.1056/nejmct1114348

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017 · 13,030 citations
2Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.1988 · 225 citations
3Mice carrying a CD20 gene disruption1998 · 128 citations
4CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.1999 · 95 citations
5Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD201994 · 1,940 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017 · 13,030 citations
2Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.1988 · 225 citations
3Mice carrying a CD20 gene disruption1998 · 128 citations
4CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.1999 · 95 citations
5Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD201994 · 1,940 citations